A Novel Photosensitizer Znln2S4 Mediated Photodynamic Therapy Induced-HepG2 Cell Apoptosis

Photodynamic therapy (PDT) uses a combination of photosensitizers with visible light to generate reactive species and selectively kill tumor or unwanted tissue. Znln(2)S(4) nanoparticles are widely implemented in photovoltaic device materials and photolysis water catalysts owing to their unique photoelectric properties. Whether Znln(2)S(4) itself can be used as an effective dye in PDT is still unknown. To determine the effects and potential mechanism of Znln(2)S(4) PDT on HepG2 cell apoptosis, electron microscopic analysis was performed to monitor the apoptotic morphology of HepG2 cells upon exposure to Znln(2)S(4)-PDT. Flow cytometry was performed to measure the apoptosis rate and intracellular ROS production. Western blot and ELISA were performed to reveal the expression changes in Bax, caspase-3 and caspase-9. Data from this work suggested that cells exhibited the typical apoptotic morphology in response to Znln(2)S(4) -PDT, with high apoptotic rate. The intracellular ROS production after ZnlnA-PDT occurred in a dose-dependent manner. Moreover, Znln(2)S(4)-PDT augmented the expression levels of pro-apoptosis factors, especially, Bax, caspase-3 and caspase-9. Taken together, our novel findings, Znln(2)S(4) -PDT elicited HepG2 cell apoptosis, suggesting Znln(2)S(4), as a promising photosensitizer candidate for cancer therapy. (C) 2019 by Radiation Research Society